Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Transcutaneous Auricular Vagus Nerve Stimulation as a Treatment for Neuropathic Pain Following Spinal Cord Injury

Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) as an Anti-inflammatory Strategy for the Treatment of Neuropathic Pain Following Spinal Cord Injury

This pilot randomized, double-blind, sham-controlled clinical investigation will evaluate the feasibility and safety of a 30-day home-based transcutaneous auricular vagus nerve stimulation (taVNS) intervention in adults with spinal cord injury (SCI) and neuropathic pain. Participants will be randomized to receive either active taVNS targeting the auricular branch of the vagus nerve or sham taVNS delivered to the earlobe. Primary outcomes include feasibility, safety, adherence, acceptability, and blinding success. Exploratory outcomes include changes in neuropathic pain, systemic inflammatory biomarkers, vagal tone assessed via heart rate variability, and quality of life.

Przegląd badań

Szczegółowy opis

Neuropathic pain is a common and debilitating complication following spinal cord injury (SCI) and is frequently resistant to pharmacologic treatment. Chronic neuroinflammation and reduced vagal tone are increasingly recognized contributors to persistent neuropathic pain after SCI. The vagus nerve plays a central role in immune regulation and descending pain modulation.

Transcutaneous auricular vagus nerve stimulation (taVNS) is a noninvasive neuromodulation technique that stimulates vagal afferent fibers via the external ear. Prior Health Canada-authorized trials conducted by the investigative team have demonstrated the feasibility, safety, and autonomic effects of taVNS in individuals with SCI.

This single-site, randomized, double-blind, sham-controlled pilot study will enroll 32 adults with SCI and neuropathic pain. Participants will be randomized 1:1 to receive either active or sham taVNS for 4 hours per day over a 30-day home-based intervention period. Outcomes will be assessed at baseline and immediately post-intervention. Feasibility and safety outcomes are primary, while exploratory clinical and mechanistic outcomes will inform the design of a future definitive randomized controlled trial.

Typ studiów

Interwencyjne

Zapisy (Szacowany)

32

Faza

  • Nie dotyczy

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Kopia zapasowa kontaktu do badania

  • Nazwa: Joy Jiang
  • Numer telefonu: 42570 519 646 6100
  • E-mail: fjiang63@uwo.ca

Lokalizacje studiów

    • Ontario
      • London, Ontario, Kanada, N6C0A7
        • Parkwood Institute, St Joseph's Health Care London
        • Kontakt:
        • Kontakt:

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

  • Dorosły
  • Starszy dorosły

Akceptuje zdrowych ochotników

Nie

Opis

Inclusion Criteria:

  • SCI of any level or severity
  • 18 years of age or older
  • current neuropathic pain
  • on no medications or on a stable prescribed dose (no change in prior 6-weeks) of anti-inflammatory, pain medications and/or depression medications

Exclusion Criteria:

  • Prone to autonomic dysreflexia
  • presence of cardiovascular disease
  • pacemaker or other implanted electrical device
  • cerebral shunts
  • epilepsy
  • pregnant or attempting to become pregnant
  • current wound/infection
  • unstable dose of prescribed anti-inflammatory, depression, or pain medications within past 6-weeks.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Poczwórny

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Active taVNS
Participants receive active transcutaneous auricular vagus nerve stimulation delivered via the cymba conchae of the left ear using the using the tVNS R device (taVNS Technologies, Erlangen, Germany) for 4 hours per day for 30 days.
Stimulation will target the auricular branch of the vagus nerve by applying stimulation to the cymba conchae region of the ear using the tVNS R device (taVNS Technologies, Erlangen, Germany). To achieve adequate stimulation while avoiding unpleasant or painful sensations, the stimulation intensity will be gradually increased in increments of 0.1mA (milliamps) until the subjective pain threshold is reached, and then reduced to a stimulus intensity just below the individuals pain threshold (expected range based on prior studies 1 - 3.2mA). Pulse width will be set at 100μs (microseconds) and frequency will be set at 25Hz (Hertz). Parameters will be set for the duration of the intervention consisting of 4 hours of daily stimulation for a period of 30 days.
Pozorny komparator: Sham taVNS
Stimulation will target the ear lobe using the tVNS R device (taVNS Technologies, Erlangen, Germany) for 4 hours per day for 30 days. Stimulation will be applied to the ear lobe in order to ensure participant feel the stimulation while avoiding activation of the vagus nerve.
Stimulation will target the ear lobe using the tVNS R device (taVNS Technologies, Erlangen, Germany). To achieve adequate stimulation while avoiding unpleasant or painful sensations, the stimulation intensity will be gradually increased in increments of 0.1mA until the subjective pain threshold is reached, and then reduced to a stimulus intensity just below the individuals pain threshold (expected range based on prior studies 1 - 3.2mA). Pulse width will be set at 100μs and frequency will be set at 25Hz. Participants will perform 4 hours of stimulation per day for a period of 30 days. Stimulation will be applied to the ear lobe in order to ensure participant feel the stimulation while avoiding activation of the vagus nerve.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Częstość występowania zdarzeń niepożądanych wynikających z leczenia podczas interwencji
Ramy czasowe: 30 dni
Wszystkie zdarzenia niepożądane, które wystąpią podczas interwencji, będą rejestrowane podczas rozmów telefonicznych i/lub wizyt badawczych odbywających się dwa razy w tygodniu i porównywane pomiędzy aktywnymi i pozorowanymi warunkami taVNS. Rejestrowany będzie opis zdarzenia niepożądanego, liczba zdarzeń i całkowita liczba uczestników, których to dotyczy.
30 dni
Success of Participant and Investigator Blinding
Ramy czasowe: Day 30
Blinding success will be assessed after completion of the intervention by asking participants and investigators to indicate which treatment group they believe the participant was assigned to (active taVNS or sham taVNS). Blinding effectiveness will be quantified using the James Blinding Index, calculated separately for participants and investigators. Blinding outcomes will be summarized descriptively.
Day 30
Recruitment Rate and Time to Recruit Target Sample Size
Ramy czasowe: Up to 20 months
Recruitment feasibility will be assessed by documenting the number and proportion of eligible individuals who consent to participate and the total time required to recruit the target sample of 32 participants. Recruitment rate will be calculated as the percentage of eligible candidates who agree to participate. These data will be summarized descriptively for the overall study population.
Up to 20 months
Retention and Attrition During the 30-Day Intervention
Ramy czasowe: 30 days
Retention will be assessed as the proportion of enrolled participants who complete the full 30-day intervention and post-intervention assessment. Attrition will be recorded as the number and proportion of participants who withdraw prior to study completion. Reasons for withdrawal or loss to follow-up will be documented where available. Retention and attrition rates will be summarized and compared descriptively between the active taVNS and sham taVNS groups.
30 days
Adherence to Daily taVNS Stimulation Prescription
Ramy czasowe: 30 days
Adherence will be assessed using automated usage data recorded by the taVNS device and associated smartphone application. Daily adherence will be calculated as the percentage of the prescribed 4-hour daily stimulation period completed (actual stimulation time divided by prescribed stimulation time × 100). Overall adherence will be summarized as the mean daily adherence across the 30-day intervention period. Adherence will be compared descriptively between the active taVNS and sham taVNS groups.
30 days
Acceptability with the taVNS intervention
Ramy czasowe: Day 30
Participant acceptability will be assessed at the end of the intervention using the Acceptability of Intervention Measure (AIM). Acceptability scores will be summarized descriptively and compared between the active taVNS and sham taVNS conditions.
Day 30

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Change in Circulating C-Reactive Protein
Ramy czasowe: Baseline and Day 30
Plasma concentrations of C-reactive protein (CRP) will be measured from fasting blood samples collected at baseline and at the end of the intervention. Concentrations will be reported in milligrams per liter (mg/L), with higher values indicating greater systemic inflammation. Change values will be calculated as post-intervention values minus baseline values and summarized descriptively between the active taVNS and sham taVNS groups.
Baseline and Day 30
Change in Circulating Interleukin-1 Beta
Ramy czasowe: Baseline and Day 30
Plasma concentrations of interleukin-1 beta (IL-1β) will be measured from fasting blood samples collected at baseline and at the end of the intervention. Concentrations will be reported in picograms per milliliter (pg/mL), with higher values indicating greater pro-inflammatory activity. Change values will be calculated as post-intervention values minus baseline values and summarized descriptively between the active taVNS and sham taVNS groups.
Baseline and Day 30
Change in Circulating Interleukin-6
Ramy czasowe: Baseline and Day 30
Plasma concentrations of interleukin-6 (IL-6) will be measured from fasting blood samples collected at baseline and at the end of the intervention. Concentrations will be reported in picograms per milliliter (pg/mL), with higher values indicating greater pro-inflammatory activity. Change values will be calculated as post-intervention values minus baseline values and summarized descriptively between the active taVNS and sham taVNS groups.
Baseline and Day 30
Change in Circulating Interferon Gamma
Ramy czasowe: Baseline and Day 30
Plasma concentrations of interferon gamma (IFN-γ) will be measured from fasting blood samples collected at baseline and at the end of the intervention. Concentrations will be reported in picograms per milliliter (pg/mL), with higher values indicating greater pro-inflammatory activity. Change values will be calculated as post-intervention values minus baseline values and summarized descriptively between the active taVNS and sham taVNS groups.
Baseline and Day 30
Change in Circulating Tumor Necrosis Factor Alpha
Ramy czasowe: Baseline and Day 30
Plasma concentrations of tumor necrosis factor alpha (TNF-α) will be measured from fasting blood samples collected at baseline and at the end of the intervention. Concentrations will be reported in picograms per milliliter (pg/mL), with higher values indicating greater pro-inflammatory activity. Change values will be calculated as post-intervention values minus baseline values and summarized descriptively between the active taVNS and sham taVNS groups.
Baseline and Day 30
Change in Neuropathic Pain Assessed by the Neuropathic Pain Symptoms Inventory
Ramy czasowe: Baseline and Day 30
Neuropathic pain severity and interference will be assessed using the Neuropathic Pain Symptoms Inventory (NPSI), a self-reported questionnaire with total scores ranging from 0 to 100, where higher scores indicate greater neuropathic pain severity and pain-related interference. Change scores will be calculated as post-intervention values minus baseline values. Mean changes and variability will be summarized and compared descriptively between the active taVNS and sham taVNS groups.
Baseline and Day 30
Change in Neuropathic Pain Assessed by the International Spinal Cord Injury Pain Basic Data Set (version 3)
Ramy czasowe: Baseline and Day 30
Neuropathic pain severity and pain-related interference will be assessed using the International Spinal Cord Injury Pain Basic Data Set (ISCIPBDS), version 3, which includes numeric rating scales ranging from 0 to 10, where higher scores indicate greater pain intensity and greater pain-related interference. Change scores will be calculated as post-intervention values minus baseline values. Mean changes and variability will be summarized and compared descriptively between the active taVNS and sham taVNS groups.
Baseline and Day 30
Change in Vagal Tone Assessed by Heart Rate Variability
Ramy czasowe: Baseline and Day 30
Vagal tone will be assessed using heart rate variability (HRV) derived from a 5-minute resting electrocardiogram recording. Root mean square of successive differences (RMSSD) and high-frequency power will be calculated using standard HRV analysis procedures. Change in HRV measures from baseline to post-intervention will be summarized descriptively and compared between the active taVNS and sham taVNS groups.
Baseline and Day 30
Change in Health-Related Quality of Life
Ramy czasowe: Baseline and Day 30
Quality of life will be assessed using selected short forms from the Spinal Cord Injury-Quality of Life (SCI-QOL) measurement system, including Pain Interference, Depression, and Positive Affect and Well-Being domains. Scores will be calculated as standardized T-scores. Change in quality-of-life scores from baseline to post-intervention will be summarized and compared descriptively between treatment groups.
Baseline and Day 30

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Szacowany)

1 października 2026

Zakończenie podstawowe (Szacowany)

1 maja 2028

Ukończenie studiów (Szacowany)

30 sierpnia 2028

Daty rejestracji na studia

Pierwszy przesłany

7 kwietnia 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

7 maja 2026

Pierwszy wysłany (Rzeczywisty)

15 maja 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

15 maja 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

7 maja 2026

Ostatnia weryfikacja

1 kwietnia 2026

Więcej informacji

Terminy związane z tym badaniem

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

NIE

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj